USP22 and COVID-19: Artificial induction of Usp22 or restoration of the deficient Usp22 production, probably as a result of genetic variations such as single-nucleotide polymorphism, might defend patients having, for example, COVID-19 or hepatitis C infection from an unfavorable course of infection marked by severe immunopathology and prevent the occurrence of autoimmune diseases.